Results 141 to 150 of about 2,071 (176)
Bimekizumab versus Adalimumab in Plaque Psoriasis
New England Journal of Medicine, 2021 Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.We randomly assigned patients with moderate-to-severe ...
Richard B. Warren +12 more
core +6 more sources
Bimekizumab versus Secukinumab in Plaque Psoriasis
New England Journal of Medicine, 2021 Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.In this phase 3b trial, we randomly ...
Reich, Kristian +12 more
openaire +3 more sources
Bimekizumab: A Review in Psoriatic Arthritis
DrugsAlthough several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, are approved for psoriatic arthritis, the treatment of this disease remains suboptimal. Bimekizumab (Bimzelx®), a dual IL-17A and IL-17F inhibitor, is approved in the EU, Great Britain and Japan for the treatment of psoriatic ...
Tina Nie, Matt Shirley
openaire +3 more sources
Canadian Journal of Health TechnologiesWhat Is the Reimbursement Recommendation for Bimzelx? The Canada’s Drug Agency (CDA-AMC) Canadian Drug Expert Committee (CDEC) recommends that Bimzelx be reimbursed by public drug plans for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) with an inadequate response to conventional systemic therapy for HS only if ...
CDA-AMC
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Bimekizumab for The Treatment of Psoriasis
ImmunotherapyPsoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common ...
Kenneth Gordon
exaly +3 more sources
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
Expert Opinion on Drug Safety, 2023 Introduction: Biological treatments deeply changed the management of moderate to severe forms of psoriasis. Among available biological therapies, interleukin (IL)-17 inhibitors, secukinumab, ixekizumab, brodalumab, and bimekizumab, represent one of the ...
Alessia Villani +2 more
exaly +2 more sources
Drugs of Today, 2022
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper 17 (Th17) immune axis, highly effective, targeted biologic therapies have been developed, shifting ...
Maria Alexandra, Rodrigues +2 more
openaire +2 more sources
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper 17 (Th17) immune axis, highly effective, targeted biologic therapies have been developed, shifting ...
Maria Alexandra, Rodrigues +2 more
openaire +2 more sources
Bimekizumab for the Treatment of Psoriasis
Drugs, 2021Psoriasis is a chronic, systemic, immune-mediated disease, with prominent skin and joint manifestations, associated with several comorbidities. In the past few decades, advances in the knowledge of psoriasis pathogenesis have driven the development of highly effective targeted biologic therapies, transforming the treatment landscape of psoriasis ...
Egídio Freitas +2 more
openaire +2 more sources
Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies [PDF]
RheumatologyObjectives: To evaluate 1-year bimekizumab efficacy in psoriatic arthritis (PsA) from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire.
Ana-Maria Orbai +2 more
exaly +2 more sources